Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2009-04-21 to 2009-07-27

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2009

Report date:

2009

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Version / remarks:

17 December 2001

GLP compliance:

yes (incl. QA statement)

Test type:

acute toxic class method

Test material

Test material information

Constituent 1

Reference substance name:

Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate

EC Number:

875-892-5

Cas Number:

1375799-59-9

Molecular formula:

C13 H14 N8 O2 . Na

IUPAC Name:

Sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate

Test animals

Species:

rat

Strain:

Wistar

Remarks:

HsdCpb:Wu

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Harlan GmbH, 5960 AD Horst, Netherlands
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 10 - 12 weeks
- Weight at study initiation: 160 g - 197 g
Fasting period before study: 16-24 h
- Housing: The animals were group caged conventionally in polycarbonate cages on low dust
wood granulate bedding (Lignocel BK 8-15, Finna Rettenmaier, Germany).
- Diet (e.g. ad libitum): ad libitum, “Provimi Kliba 3883 PM S15 Maus/Ratte Haltung, Kaiseraugst Switzerland”,
- Water (e.g. ad libitum): ad libitum, tap water
- Acclimation period: at least 5 days
- Method of randomisation in assigning animals to test and control groups

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 55 ± 5
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

polyethylene glycol

Remarks:

polyethylene-glycol 400

Details on oral exposure:

VEHICLE
- Concentration in vehicle: 30 and 200 mg/mL
- Amount of vehicle (if gavage): 10 mL/kg bw


CLASS METHOD (if applicable) Acute toxic class
- Rationale for the selection of the starting dose: as described in the OECD test guideline

Doses:

Three animals are used for each step. The dose level to be used as the starting dose is selected from one of four fixed levels, 5, 50, 300 and 2000 mg/kg body weight.
The starting dose level should be that which is most likely to produce mortality in some of the dosed animals. Absence or presence of compound-related mortality of the animals dosed at one step will determine the next step, i.e.:
- no further testing is needed,
- dosing of three additional animals, with the same dose,
- dosing of three additional animals at the next higher or the next lower dose level.
The substance is tested using a stepwise procedure, each step using three animals of a single sex (normally females). The procedure is described in the flow charts of Annex 2, OECD guideline 423.

No. of animals per sex per dose:

3

Control animals:

no

Details on study design:

- Duration of observation period following administration: 21 days
- Frequency of observations and weighing: Clinical signs and mortality rates were determined several times on the day of administration and subsequently at least once daily for an observation period of at least 14 to 21 days. Mortality and in the event of symptoms occurring, nature, duration and intensity were recorded individually. The day of administration is defined as day 1. Times after administration until the following day were recorded either in minutes or in hours, depending on what was appropriate.
- Necropsy of survivors performed: yes
- Clinical signs including body weight: The weight gain of the animals was checked weekly until the end of the studies.
- Other examinations performed: clinical signs, body weight,

Statistics:

The LD50 were estimated according to OECD - Guideline for Testing of Chemicals No. 423 - "Acute Oral Toxicity - Acute Toxic Class Method"; adopted: December 17, 2001

Results and discussion

Effect levels

Key result

Sex:

female

Dose descriptor:

LD50 cut-off

Effect level:

2 500 mg/kg bw

Based on:

test mat.

Mortality:

One animal died during observation period after administration of 2000 mg/kg bw

Clinical signs:

other: piloerection, blood-crusted snout, decreased motility, spasmodic state, high legged gait, sunken flanks, decreased food intake, decreased water intake, tachypnea, emaciation, poor general condition, hunched posture, staggering gait and narrowed palpebral

Gross pathology:

In the animal that died during the observation period, no other gross pathological changes than cannibalism were detected.
In the necropsy performed at the end of the post-treatment observation period in the surviving animals, no gross pathological changes were detected.

Any other information on results incl. tables

Dose mg/kg bw	Toxicological result*			Occurrence of signs	Time of death	Mortality (%)
female
(1st) 2000	0	3	3	3d -17d**	--	0
(2nd) 2000	1	3	3	3d – 16d**	10d	33
* number of animals which died spontaneously and/or were sacrificed in moribund state / number of animals with signs of toxicity / total number of animals used per group
** (because of the severity and duration of symptoms the post treatment observation phase of the acute oral toxicity in rats was extended to three weeks)
LD50 cut-off: 2500 mg/kg bw (according to OECD guideline 423)

Applicant's summary and conclusion

Interpretation of results:

Category 5 based on GHS criteria

Remarks:

according to Annex 2d of OECD guideline 423

Conclusions:

In the present study which was conducted equivalent to OECD test guideline 423, female Wistar rats (3/group) were orally administered a single dose Molidustat and were observed for the following 21 days. The doses applied were. 5, 50, 300, and 2000 mg/kg bw. One animal died after the administration of 2000 mg/kg bw Molidustat. The following clinical signs were observed: piloerection, blood-crusted snout, decreased motility, spasmodic state, high legged gait, sunken flanks, decreased food intake, decreased water intake, tachypnea, emaciation, poor general condition, hunched posture, staggering gait and narrowed palpebral fissure. There was a significant loss of body weight on day 8 of the study in the rats treated with 2000 mg/kg bw. In the animal that died during the observation period no other changes than cannibalism was detected. In the necropsy performed at the end of the post-treatment observation period no gross pathological changes were detected . Based on these results the LD50 cut-off value for acute oral toxicity is considered 2500 mg/kg bw.

Executive summary:

In an acute oral toxicity study similar to OECD test guideline 423, groups of fasted, 10-12 weeks old female Wistar rats (3/group) were given a single oral dose of Molidustat in ethylene glycol  at doses of 5, 50, 300,and 2000 mg/kg bw and observed for 21 days.

Oral LD50 cut-off Females = 2500 mg/kg bw

 

One animal treated with 2000 mg/kg bw died during the observation period. The following clinical signs were observed: piloerection, blood-crusted snout, decreased motility, spasmodic state, high legged gait, sunken flanks, decreased food intake, decreased water intake, tachypnea, emaciation, poor general condition, hunched posture, staggering gait and narrowed palpebral fissure. There was a significant loss of body weight on day 8 of the study in the rats treated with 2000 mg/kg bw. In the animal that died during the observation period no other changes than cannibalism was detected. In the necropsy performed at the end of the post-treatment observation period no gross pathological changes were detected .

 

Molidustat is of low Toxicity based on the LD50 cut-off in female Wistar rats, thus, no classification is needed according to Regulation (EU) No. 1272/2008 (CLP).